Published in Mol Ther on April 06, 2017
Nanoparticle Technology: Having Impact, but Needing Further Optimization. Mol Ther (2017) 0.75
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release (2012) 3.41
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature (2015) 3.06
Non-viral vectors for gene-based therapy. Nat Rev Genet (2014) 3.04
Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm (2005) 2.88
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
The insider's guide to leukocyte integrin signalling and function. Nat Rev Immunol (2011) 2.71
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet (2015) 2.71
Progress towards in vivo use of siRNAs. Mol Ther (2006) 2.56
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release (2005) 2.47
Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol (2006) 2.30
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
Mammalian RNAi for the masses. Trends Genet (2003) 2.27
The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med (2005) 2.24
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
Chemical modification of siRNAs for in vivo use. Oligonucleotides (2008) 2.03
Transmembrane proteins of tight junctions. Biochim Biophys Acta (2007) 2.02
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest (2011) 1.92
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature (2010) 1.73
Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A (2007) 1.58
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55
Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug Chem (2002) 1.55
Time domain dielectric spectroscopy study of human cells. II. Normal and malignant white blood cells. Biochim Biophys Acta (1999) 1.54
Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol (2015) 1.53
Analysis on the current status of targeted drug delivery to tumors. J Control Release (2012) 1.48
Efficiency of RNA interference in the mouse hematopoietic system varies between cell types and developmental stages. Mol Cell Biol (2005) 1.37
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials (2010) 1.35
Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol (2006) 1.27
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids (2012) 1.24
Special delivery: targeted therapy with small RNAs. Gene Ther (2011) 1.22
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest (2014) 1.22
Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet (2015) 1.19
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir (2012) 1.13
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Lack of heparan sulfate expression in B-cell lines: implications for Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 infections. J Virol (2008) 1.03
Chemokine triggered integrin activation and actin remodeling events guiding lymphocyte migration across vascular barriers. Exp Cell Res (2011) 1.01
A daunting task: manipulating leukocyte function with RNAi. Immunol Rev (2013) 1.00
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods (2011) 0.97
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest (2014) 0.96
Lymphocyte apoptosis: induction by gene transfer techniques. Gene Ther (1997) 0.96
Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol (2015) 0.93
Nucleotide-binding and oligomerization domain-like receptors and retinoic acid inducible gene-like receptors in human tonsillar T lymphocytes. Immunology (2011) 0.92
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials (2015) 0.89
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano (2015) 0.88
Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection. Biochem J (2013) 0.87
RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. PLoS One (2012) 0.86
Leukemia-specific siRNA delivery by immunonanoplexes consisting of anti-JL1 minibody conjugated to oligo-9 Arg-peptides. Mol Cells (2010) 0.86
Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov (2016) 0.85
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide. Mol Ther (2014) 0.85
Asymmetric peptide dendrimers are effective linkers for antibody-mediated delivery of diverse payloads to b cells in vitro and in vivo. Pharm Res (2014) 0.85
Dendrimers for siRNA Delivery. Pharmaceuticals (Basel) (2013) 0.82
In vivo toxicity of cationic micelles and liposomes. Nanomedicine (2014) 0.81
Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality. Bioconjug Chem (2016) 0.81
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A (2015) 0.81
Dendrimer Nanovectors for SiRNA Delivery. Methods Mol Biol (2016) 0.80
Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. J Control Release (2016) 0.80
Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs. J Immunother (2013) 0.80
Aptamer-Targeted Attenuation of IL-2 Signaling in CD8(+) T Cells Enhances Antitumor Immunity. Mol Ther (2017) 0.79
Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle (2009) 0.79
Cationic phosphonolipids as non viral vectors for DNA transfection in hematopoietic cell lines and CD34+ cells. Blood Cells Mol Dis (1997) 0.79
Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems. J Phys Chem B (2015) 0.78
Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection. J Control Release (2014) 0.77
Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. Biotechniques (1995) 0.77
TNF-alpha secretion and apoptosis of lymphocytes mediated by gene transfer. Cytokines Cell Mol Ther (1999) 0.76
The two hit hypothesis: an improved method for siRNA-mediated gene silencing in stimulated primary human T cells. J Immunol Methods (2013) 0.76
Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. J Drug Target (2016) 0.76
Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response. Mol Ther (2017) 0.75